MET Inhibition in Clear Cell Renal Cell Carcinoma

@inproceedings{Xie2016METII,
  title={MET Inhibition in Clear Cell Renal Cell Carcinoma},
  author={Zuoquan Xie and Young Hwa Lee and Marta Boeke and Lucia Beatrice Jilaveanu and Zongzhi Z. Liu and Donald P Bottaro and Harriet M. Kluger and Brian Shuch},
  booktitle={Journal of Cancer},
  year={2016}
}
BACKGROUND Clear cell renal cell carcinoma (ccRCC) is the most lethal form of kidney cancer. Small molecule VEGFR inhibitors are widely used but are not curative and various resistance mechanisms such as activation of the MET pathway have been described. Dual MET/VEGFR2 inhibitors have recently shown clinical benefit but limited preclinical data evaluates their effects in ccRCC. METHODS An interrogation of the Cancer Genome Atlas (TCGA) dataset was performed to evaluate oncogenic alterations… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial

  • N Haas, J Manola, R Uzzo, M Atkins, G Wilding, M Pins
  • J Clin Oncol
  • 2015
1 Excerpt

Similar Papers

Loading similar papers…